Osugi Yuko, Yagasaki Hiroshi, Sako Masahiro, Kosaka Yoshiyuki, Taga Takashi, Ito Tsuyoshi, Yamamoto Masuji, Ohara Akira, Sato Takeyuki, Mimaya Junichi, Tsukimoto Ichiro, Kojima Seiji
Dept. of Pediatrics, Osaka General Medical Center, Osaka, Japan.
Haematologica. 2007 Dec;92(12):1687-90. doi: 10.3324/haematol.11359.
We analyzed the outcomes of 44 children with hepatitis associated aplastic anemia (HAA) who received immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporine (CsA). Fourteen (31.8%) patients achieved complete response and 17 (38.6%) achieved partial response, for an overall response rate of 70.4% after 6 months. Seven non-responders received bone marrow transplantation from an HLA-matched unrelated donor and 6 out of 7 are alive. The probability of overall survival at 10 years was 88.3+/-4.9%, which supports the role of IST with ATG and CsA as treatment of choice for children with HAA without an HLA identical sibling donor.
我们分析了44例接受抗胸腺细胞球蛋白（ATG）和环孢素（CsA）免疫抑制治疗（IST）的肝炎相关性再生障碍性贫血（HAA）患儿的治疗结果。14例（31.8%）患者获得完全缓解，17例（38.6%）获得部分缓解，6个月时总缓解率为70.4%。7例无反应者接受了来自HLA匹配无关供者的骨髓移植，7例中有6例存活。10年总生存率为88.3±4.9%，这支持了对于没有HLA全相合同胞供者的HAA患儿，使用ATG和CsA进行IST是首选治疗方法的观点。
Zotero 插件